Skip to main content
. 2022 Nov;11(11):2289–2305. doi: 10.21037/tlcr-22-732

Figure 4.

Figure 4

Kaplan-Meier survival curves of PFS and OS of patients who received ICI rechallenge treatment. (A) PFS from the first ICI treatment (PFS1). (B) PFS from the ICI rechallenge treatment (PFS2). (C) OS from the first ICI treatment (OS1). (D) OS from ICI rechallenge treatment (OS2). PFS, progression-free survival; OS, overall survival; ICI, immune checkpoint inhibitor.